Celgene (CELG) Tops Q2 EPS by 4c, Raise FY EPS Guiadnce

July 27, 2017 7:32 AM EDT

Celgene (NASDAQ: CELG) reported Q2 EPS of $1.82, $0.04 better than the analyst estimate of $1.78. Revenue for the quarter came in at $3.27 billion versus the consensus estimate of $3.23 billion.

GUIDANCE:

Celgene sees FY2017 EPS of $7.25-$7.35.

Previous 2017 Guidance

Updated 2017 Guidance
Net Product Sales
REVLIMID(®) $8.0B to $8.3B Unchanged
POMALYST(®)/IMNOVID(®) Approximately $1.6B Unchanged
OTEZLA(® ) $1.5B to $1.7B Unchanged
ABRAXANE(®) Approximately $1.0B Unchanged
Total Revenue $13.0B to $13.4B Unchanged
GAAP operating margin Approximately 46.0% Approximately 41.5%
GAAP diluted EPS $5.95 to $6.29 $5.36 to $5.62
Adjusted operating margin Approximately 57.0% Approximately 57.5%
Adjusted diluted EPS $7.15 to $7.30 $7.25 to $7.35
Weighted average diluted shares Approximately 815M Unchanged

For earnings history and earnings-related data on Celgene (CELG) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance

Related Entities

Earnings